NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026 (booth #1537).

The abstracts highlight how combining laboratory testing with clinical data can support oncology research, drive AI-based analysis, and help translate findings into clinically relevant insights. By linking testing results with real-world clinical data, NeoGenomics has demonstrated its capabilities to drive deeper characterization of biomarker prevalence, evaluation of testing concordance, and insights that help bridge translational research and clinical application, with the potential to enable cutting-edge oncology therapy development and commercialization.

"Bringing together lab and clinical data is becoming foundational to modern oncology research," said Tony Zook, CEO at NeoGenomics. "Our collaborations with biopharma partners have allowed us to develop compelling research that we're proud to present at AACR, showcasing how these insights can directly enhance therapy development and create optionality for providers and patients."

Presentations at AACR include:

  • Oral presentation (Clinical Trials Mini Symposium: Focus on ctDNA): Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): The MERIDIAN Phase II trial
    • Monday, April 20, at 2:30–4:30 PM
  • Poster #1106: Rapid identification of comprehensive multi-omic protein and RNA biomarkers on a single FFPE tissue section using a novel integrated nCounter® workflow
    • Sunday, April 19, at 2:00–5:00 PM | Section 43
  • Poster #1224: Antibody-Drug Conjugate Immuno-Oncology Panel for Comprehensive Characterization of the Tumor and Associated Microenvironment
    • Sunday, April 19, at 2:00–5:00 PM | Section 47
  • Poster #1456: Paletrra™ AI: Automated phenotyping of multiplex immunofluorescence datasets via information maximizing self-training
    • Monday, April 20, at 9:00 AM–12:00 PM | Section 4
  • Poster #1993: Real-world landscape of KMT2A and NPM1 variants and fusions in hematologic malignancies
    • Monday, April 20, at 9:00 AM–12:00 PM | Section 23
  • Poster #4162: AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens
    • Tuesday, April 21, at 9:00 AM–12:00 PM | Section 3
  • Poster #8493: Expression of the ferroptosis suppressor FSP1 but not GPX4 shows significant adverse prognostic effect in diffuse large B-cell lymphoma with wild-type TP53
    • Tuesday, April 21, at 9:00 AM–12:00 PM | Section 20
  • Poster #6674: Metabolic reprogramming in advanced renal tumors contributes to a dysfunctional immune response and immune exhaustion within the tumor microenvironment
    • Tuesday, April 21, at 2:00–5:00 PM | Section 48
  • Poster #7263: Identification of molecular alterations in soft tissue sarcoma patients with combined pan-cancer CGP and bespoke sarcoma fusion detection testing
    • Wednesday, April 22, at 9:00 AM–12:30 PM | Section 21

Attendees interested in learning more about NeoGenomics' clinical and genomics insight capabilities can connect with the team onsite at booth #1537.